List of Excipients in Branded Drug PRALATREXATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fresenius Kabi USA LLC	PRALATREXATE	pralatrexate	65219-550	HYDROCHLORIC ACID
Fresenius Kabi USA LLC	PRALATREXATE	pralatrexate	65219-550	SODIUM CHLORIDE
Fresenius Kabi USA LLC	PRALATREXATE	pralatrexate	65219-550	SODIUM HYDROXIDE
Fresenius Kabi USA LLC	PRALATREXATE	pralatrexate	65219-550	WATER

Generic Drugs Containing PRALATREXATE

Company	Ingredient	NDC	Excipient
DrReddy's Laboratories Inc	pralatrexate	43598-342	HYDROCHLORIC ACID
DrReddy's Laboratories Inc	pralatrexate	43598-342	SODIUM CHLORIDE
DrReddy's Laboratories Inc	pralatrexate	43598-342	SODIUM HYDROXIDE
DrReddy's Laboratories Inc	pralatrexate	43598-342	WATER

What are the Most Frequently-Used Excipients in PRALATREXATE?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	WATER

Excipient Strategy and Commercial Opportunities for Pralatrexate

Last updated: February 27, 2026

What role do excipients play in pralatrexate formulations?

Excipients in pralatrexate formulations serve to stabilize the active ingredient, improve bioavailability, and facilitate manufacturing. Common excipients include buffers, stabilizers, and solubilizers such as sodium chloride, sodium phosphate, and polysorbates. The choice of excipients directly affects the drug's stability, shelf life, and delivery method.

Which excipients are currently utilized in pralatrexate products?

The FDA-approved formulation for pralatrexate (brand: Folotyn) predominantly employs a sodium chloride solution as a diluent for intravenous administration. The excipient profile ensures isotonicity and compatibility with infusion equipment.

Excipients	Function	Usage (per infusion)	Notes
Sodium chloride	Isotonicity	4.2 mg/mL	Maintains osmolarity
Water for injection	Solvent	-	Solubilizes active drug

How can excipient strategy expand commercial opportunities?

1. Formulation Innovation

   Developing new formulations that improve stability, reduce injection volume, or enable alternate delivery routes offers differentiation. For instance, converting pralatrexate to a lyophilized powder with stabilizers could extend shelf life and ease storage logistics.

2. Parenteral and Non-Parenteral Delivery

   While current formulations are IV-only, research into excipients enabling oral or subcutaneous delivery could open new markets. Mucoadhesive excipients or permeation enhancers could facilitate this shift.

3. Biosimilar and Generic Development

   Optimizing excipient profiles for biosimilar versions can reduce manufacturing costs and improve stability. Excipients that enhance scalability or simplify sterilization further lower entry barriers.

4. Focused Excipients for Reduced Toxicity

   Identifying excipients that minimize infusion-related reactions or hypersensitivity could improve patient compliance and safety, facilitating wider adoption in treatment protocols.

What are the regulatory considerations?

Regulators demand comprehensive documentation on excipient purity, compatibility, and safety profiles. Changes in excipient composition require bioequivalence demonstrations. For biosimilar and generic products, the excipient profile must match the reference product’s specifications.

What commercial opportunities are available in excipient development?

• Custom Excipient Formulation: Developing proprietary stabilizers or solubilizers specific to pralatrexate can create licensing or partnership opportunities.

• Contract Manufacturing of Excipient-Enhanced Formulations: Contract manufacturing organizations (CMOs) can offer specialized formulation services for novel or improved pralatrexate products.

• Supply Chain Optimization: Securing high-purity excipient supply chains reduces manufacturing risk and enhances product reliability, attractive to pharmaceutical companies expanding globally.

How does competition influence excipient strategy?

Most competitors focus on optimizing existing formulations for stability and safety. Opportunities exist in creating innovative excipient combinations that permit novel delivery methods or improve patient experience. Early investment in such platforms can capture market share in emerging indications or administration routes.

What are the key trends impacting excipient strategy?

• Increasing focus on patient-centric formulations, such as low-volume or oral forms.
• Rising demand for excipients that improve stability in cold-chain logistics.
• Emphasis on excipients that reduce manufacturing costs without compromising safety.
• Regulatory pressure to identify excipients with well-documented safety profiles.

Key Takeaways

• Excipients in pralatrexate formulations primarily maintain stability and compatibility for IV infusion.
• Opportunities exist in developing alternative formulations, including oral or subcutaneous options.
• Regulatory requirements demand detailed safety and compatibility data for excipient modifications.
• Innovation in excipient design can lead to competitive differentiation, cost reduction, and expanded indications.
• Supply chain reliability and safety profile improvements offer commercial advantages.

FAQs

1. Can excipient enhancements improve pralatrexate shelf life?
Yes, incorporating stabilizers or protective agents can increase shelf life, reducing storage and transportation costs.

2. Are oral formulations of pralatrexate feasible with excipient modifications?
Potentially, but would require overcoming bioavailability challenges with permeation enhancers or novel delivery systems.

3. How does excipient choice impact regulatory approval?
Excipients must be safe, compatible, and supported by stability data. Changes necessitate regulatory review and possible bioequivalence studies.

4. What non-active ingredient innovations could open new markets?
Developing excipients that allow for sustained-release or targeted delivery can expand clinical applications.

5. Is there a market for custom excipients in pralatrexate formulations?
Yes, proprietary excipients tailored to pralatrexate’s stability and delivery needs can provide competitive advantage and licensing opportunities.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Initiatives to Improve Reporting of Pharmacokinetic and Toxicological Data.
[2] Pharmacopeial Convention. (2021). USP <1078> Excipients.
[3] European Medicines Agency. (2020). Guideline on Choice of Excipient in Human Medicinal Products.